



**OMEGA DIAGNOSTICS GROUP PLC  
("Omega" or the "Company" or the "Group")**

**Statement regarding share price movement**

Omega (AIM: ODX), the medical diagnostics company focused on CD4, food intolerance and allergy testing, notes the recent rise in the Company's share price and confirms that it is not aware of any material reason for the significant increase.

As previously announced the Company continues to work with its partner Mologic Ltd with regards its first generation ELISA antibody test for COVID-19 and also with the UK Rapid Test Consortium, which is jointly developing, and will manufacture, a Point-of-Care COVID-19 lateral flow antibody test.

In respect of both these opportunities the Company will keep the market informed as matters develop.

In a Sky News interview earlier today, the introduction referred to the Consortium being able to make 50m tests a year, a figure also referred to in a newspaper article published on 26 April 2020. This is not a figure that relates to the potential output from Omega and its manufacturing facilities alone.

**Contacts:**

**Omega Diagnostics Group PLC**

Bill Rhodes, Interim Non-Executive Chairman  
Colin King, Chief Executive  
Kieron Harbinson, Group Finance Director

Tel: 01259 763 030  
[www.omegadiagnostics.com](http://www.omegadiagnostics.com)

**finnCap Ltd**

Geoff Nash/Hannah Boros (Corporate Finance)  
Camille Gochez (ECM)

Tel: 020 7220 0500

**Walbrook PR Limited**

Paul McManus  
Lianne Cawthorne

Tel: 020 7933 8780 or [omega@walbrookpr.com](mailto:omega@walbrookpr.com)  
Mob: 07980 541 893  
Mob: 07584 391 303